🚀 VC round data is live in beta, check it out!
Hansoh Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hansoh Pharma and similar public comparables like Celltrion, Revolution Medicines, Insmed, Astellas Pharma and more.
Hansoh Pharma Overview
About Hansoh Pharma
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Founded
2015
HQ
Employees
9.0K
Website
Sectors
Financials (LTM)
EV
$26B
Hansoh Pharma Financials
Hansoh Pharma reported last 12-month revenue of $2B and EBITDA of $912M.
In the same LTM period, Hansoh Pharma generated $2B in gross profit, $912M in EBITDA, and $820M in net income.
Revenue (LTM)
Hansoh Pharma P&L
In the most recent fiscal year, Hansoh Pharma reported revenue of $2B and EBITDA of $805M.
Hansoh Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $912M | XXX | $805M | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 45% | XXX | XXX | XXX |
| EBIT Margin | 37% | XXX | 33% | XXX | XXX | XXX |
| Net Profit | $820M | XXX | $641M | XXX | XXX | XXX |
| Net Margin | 36% | XXX | 36% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hansoh Pharma Stock Performance
Hansoh Pharma has current market cap of $31B, and enterprise value of $26B.
Market Cap Evolution
Hansoh Pharma's stock price is $5.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26B | $31B | -0.9% | XXX | XXX | XXX | $0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHansoh Pharma Valuation Multiples
Hansoh Pharma trades at 11.5x EV/Revenue multiple, and 28.7x EV/EBITDA.
EV / Revenue (LTM)
Hansoh Pharma Financial Valuation Multiples
As of April 19, 2026, Hansoh Pharma has market cap of $31B and EV of $26B.
Equity research analysts estimate Hansoh Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hansoh Pharma has a P/E ratio of 37.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $31B | XXX | $31B | XXX | XXX | XXX |
| EV (current) | $26B | XXX | $26B | XXX | XXX | XXX |
| EV/Revenue | 11.5x | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBITDA | 28.7x | XXX | 32.5x | XXX | XXX | XXX |
| EV/EBIT | 31.0x | XXX | 44.2x | XXX | XXX | XXX |
| EV/Gross Profit | 12.8x | XXX | 16.0x | XXX | XXX | XXX |
| P/E | 37.5x | XXX | 48.0x | XXX | XXX | XXX |
| EV/FCF | 30.0x | XXX | 53.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hansoh Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hansoh Pharma Margins & Growth Rates
Hansoh Pharma's revenue in the last 12 month grew by 13%.
Hansoh Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Hansoh Pharma's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hansoh Pharma's rule of X is 74% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Hansoh Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 53% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 27% | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hansoh Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hansoh Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Celltrion | XXX | XXX | XXX | XXX | XXX | XXX |
| Revolution Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Insmed | XXX | XXX | XXX | XXX | XXX | XXX |
| Astellas Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Daiichi Sankyo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hansoh Pharma M&A Activity
Hansoh Pharma acquired XXX companies to date.
Last acquisition by Hansoh Pharma was on XXXXXXXX, XXXXX. Hansoh Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hansoh Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHansoh Pharma Investment Activity
Hansoh Pharma invested in XXX companies to date.
Hansoh Pharma made its latest investment on XXXXXXXX, XXXXX. Hansoh Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hansoh Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hansoh Pharma
| When was Hansoh Pharma founded? | Hansoh Pharma was founded in 2015. |
| Where is Hansoh Pharma headquartered? | Hansoh Pharma is headquartered in China. |
| How many employees does Hansoh Pharma have? | As of today, Hansoh Pharma has over 9K employees. |
| Who is the CEO of Hansoh Pharma? | Hansoh Pharma's CEO is Huijuan Zhong. |
| Is Hansoh Pharma publicly listed? | Yes, Hansoh Pharma is a public company listed on HKEX. |
| What is the stock symbol of Hansoh Pharma? | Hansoh Pharma trades under 03692 ticker. |
| When did Hansoh Pharma go public? | Hansoh Pharma went public in 2019. |
| Who are competitors of Hansoh Pharma? | Hansoh Pharma main competitors are Celltrion, Revolution Medicines, Insmed, Astellas Pharma. |
| What is the current market cap of Hansoh Pharma? | Hansoh Pharma's current market cap is $31B. |
| What is the current revenue of Hansoh Pharma? | Hansoh Pharma's last 12 months revenue is $2B. |
| What is the current revenue growth of Hansoh Pharma? | Hansoh Pharma revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Hansoh Pharma? | Current revenue multiple of Hansoh Pharma is 11.5x. |
| Is Hansoh Pharma profitable? | Yes, Hansoh Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hansoh Pharma? | Hansoh Pharma's last 12 months EBITDA is $912M. |
| What is Hansoh Pharma's EBITDA margin? | Hansoh Pharma's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of Hansoh Pharma? | Current EBITDA multiple of Hansoh Pharma is 28.7x. |
| What is the current FCF of Hansoh Pharma? | Hansoh Pharma's last 12 months FCF is $871M. |
| What is Hansoh Pharma's FCF margin? | Hansoh Pharma's last 12 months FCF margin is 38%. |
| What is the current EV/FCF multiple of Hansoh Pharma? | Current FCF multiple of Hansoh Pharma is 30.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.